Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

U.S. Food and Drug Administration Approves Cangene's VARIZIG®

Published: Thursday, January 10, 2013
Last Updated: Wednesday, January 09, 2013
Bookmark and Share
Commercial distribution of product is expected in early March of 2013.

Cangene Corporation has announced that the United States Food and Drug Administration has approved VARIZIG® [Varicella Zoster Immune Globulin (Human)] for post-exposure prophylaxis of varicella (chickenpox) in high risk patient groups including immunocompromised children, newborns and pregnant women.

VARIZIG is intended to reduce the severity of chickenpox infections in these patients.

VARIZIG is a hyperimmune product that contains antibodies specific for the Varicella zoster virus which causes the viral infection known as chickenpox.

VARIZIG is approved in Canada and was previously made available in the United States under an investigational new drug (IND) Expanded Access Protocol.

Through the expanded access program, VARIZIG was available for patients at risk of severe complications of varicella, to address the unmet need in this population.

The Expanded Access Protocol will remain active until commercial product is available for distribution which is expected in early March of 2013.

VARIZIG will continue to be distributed exclusively by FFF Enterprises, Inc., a leading biopharmaceutical supplier.

"The approval of VARIZIG in the United States marks an important milestone in Cangene's history" says John A. Sedor, President and Chief Executive Officer of Cangene.

"While VARIZIG services a small niche infectious disease market, the approval of the product in the United States adds a fourth product to our commercial portfolio and reflects our patient focused strategy by addressing an ongoing medical need" added Mr. Sedor.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cangene Receives Approval for WinRho
Company has received marketing authorization approval in Portugal from INFARMED.
Monday, September 23, 2013
Cangene Awarded Biodefence Contract for AIGIV
Company has been awarded a multiple award indefinite delivery/indefinite quantity contract.
Friday, September 20, 2013
Cangene Granted Exclusive U.S. Commercialization Rights for episil® by Camurus AB
Plans product launch in October 2012.
Tuesday, July 10, 2012
Cangene Hires Vice President, Business Development
Mr. Kevin G. Taylor joins the new position of Vice President.
Wednesday, March 28, 2012
Cangene Reports Second Quarter 2012 Results
Company reports financial results, ended on January 31, 2012.
Thursday, March 15, 2012
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Flu Vaccine May Reduce Risk of Death For Type 2 Diabetes Patients
Researchers at Imperial College London have suggested that the vaccine may have substantial benefits for patients with long-term conditions.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Porphyrins as Catalysts in Scalable Organic Reactions
This review covers the most relevant scalable porphyrin-catalysed procedures, showing how these compounds represent broad applications in chemistry.
CDC Updates Zika Recommendations
CDC has issued updated Zika recommendations and guidance for healthcare providers with a focus on sexual transmission.
Exploiting Malaria’s Achilles’ Heel
Researchers have uncovered an Achilles' heel in malaria's anti-drug treatment arsenal that could lead to a disease cure.
Genome of 6000-Year-Old Barley Sequenced
Researchers have successfully sequenced the genome of Chalcolithic barley grains for the first time.
3D Models May Yield Ovarian Cancer Insights
Researchers are developing new tools to decipher ovarian cancer developments through a 3D printing technology.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Plant Compounds Fight Together Against Colon Cancer
Research shows treating colon cancer cells with curcumin, then silymarin is more effective than treatment with each individually.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!